What is Chardan Capital’s Estimate for ABUS FY2025 Earnings?

Arbutus Biopharma Co. (NASDAQ:ABUS) – Chardan Capital increased their FY2025 earnings per share estimates for shares of Arbutus Biopharma in a report issued on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will post earnings of ($0.30) per share for the year, up from their previous forecast of ($0.38). The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share.

A number of other brokerages also recently commented on ABUS. StockNews.com downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, March 13th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Price Performance

Arbutus Biopharma stock opened at $3.35 on Thursday. The business has a 50 day simple moving average of $3.33 and a 200-day simple moving average of $3.58. Arbutus Biopharma has a 12 month low of $2.30 and a 12 month high of $4.73. The stock has a market capitalization of $634.80 million, a PE ratio of -7.79 and a beta of 1.93.

Institutional Investors Weigh In On Arbutus Biopharma

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its holdings in shares of Arbutus Biopharma by 3.3% in the 4th quarter. Wellington Management Group LLP now owns 513,302 shares of the biopharmaceutical company’s stock valued at $1,678,000 after purchasing an additional 16,484 shares in the last quarter. Two Seas Capital LP increased its holdings in Arbutus Biopharma by 4.2% in the fourth quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company’s stock valued at $28,583,000 after buying an additional 353,568 shares in the last quarter. Whitefort Capital Management LP lifted its position in shares of Arbutus Biopharma by 2.9% during the 4th quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company’s stock valued at $43,301,000 after acquiring an additional 373,949 shares during the period. Woodline Partners LP boosted its stake in shares of Arbutus Biopharma by 45.4% during the 4th quarter. Woodline Partners LP now owns 971,628 shares of the biopharmaceutical company’s stock worth $3,177,000 after acquiring an additional 303,475 shares in the last quarter. Finally, Saba Capital Management L.P. grew its holdings in shares of Arbutus Biopharma by 31.3% in the 4th quarter. Saba Capital Management L.P. now owns 887,993 shares of the biopharmaceutical company’s stock worth $2,904,000 after acquiring an additional 211,566 shares during the period. 43.79% of the stock is currently owned by hedge funds and other institutional investors.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.